Suggested remit: To appraise the clinical and cost effectiveness of gosuranemab within its marketing authorisation for treating progressive supranuclear palsy.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 1607
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2019 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual